We aimed to assess the prognostic value of [18F]flotufolastat PET in patients with metastatic prostate cancer during taxane-based chemotherapy (CTx). Methods: In total, 69 patients who received CTx as well as baseline and follow-up [18F]flotufolastat PET/CT scans were included. Imaging response was assessed by visual RECIP 1.0 dichotomized into progressive disease (PD) and non-PD. Biochemical response was defined as a prostate-specific antigen decrease of greater than 50% (castration-resistant) or a decline to less than 0.2 ng/mL (hormone-sensitive). Kaplan-Meier analysis was performed regarding overall survival, and the Harrell concordance index was calculated. Results: Patients with PD showed a significantly shorter median overall survival of 12 mo (95% CI, 8.3 mo to not reached) compared with non-PD (45 mo; 95% CI, 37 mo to not reached). The Harrell concordance index for RECIP (0.84; 95% CI, 0.72-0.97; P < 0.001) was higher than biochemical response (0.66; 95% CI, 0.49-0.84; P = 0.07). Conclusion: [18F]flotufolastat PET assessed using visual RECIP has high prognostic utility in patients with metastatic prostate cancer undergoing CTx.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2026 Apr 22 [Epub ahead of print]
Sonja Kirchhoff, Bernd Erber, Isabel Rauscher, Daniel Sasse, Theo Lorenzini, Maximilian Keck, Kristina Schwamborn, Florian Siegel, Janina Werner, Florian Kirchhoff, Wolfgang Weber, Matthias Eiber, Stephan Beintner-Skawran
Department of Nuclear Medicine, School of Medicine and Health, TUM University Hospital, Munich, Germany., Institute of Pathology, School of Medicine and Health, School of Medicine, Technical University of Munich, Munich, Germany., Department of Urology, School of Medicine and Health, TUM University Hospital, Munich, Germany., Department of Nuclear Medicine, School of Medicine and Health, TUM University Hospital, Munich, Germany; .